Company: IMCR
Filing Date: 2025-03-24
Form Type: PRE 14A
Source: 0001140361-25-010035
Chunk: 105

Company: Immunocore Holdings plc
Filing Date: 2025-03-24
Form: PRE 14A
Chunk 105
---
 some. 2025 Salary Outcome The CEO requested to keep base salary flat for 2025 to increase the pool for employee salary increases. The Committee has agreed a 2025 salary increase of 0% for the CEO for this reason. This increase is not reflective of the CEO’s strong performance. 2025 Equity Grant The Committee approved an equity grant to be made to the CEO of options covering 405,824 shares in 2025 with an exercise price of $29.60 and RSUs covering 95,270 shares compared to a grant of 281,819 options with an exercise price of $70.50 in 2024. These vest in line with the Group’s equity incentive plan rules and practices set out further in this report. 2024 Remuneration Policy In 2022 we considered the activities undertaken and remuneration measures applicable during 2021 and developed a Remuneration Policy, which, following shareholder approval in 2022, has remained in place since the date of the 2021 AGM and for up to three years thereafter. This formalised a number of remuneration programs and policies effective during 2021 and which have remained until the Annual General Meeting in 2025 or until a Remuneration Policy is approved by the shareholders. The updated Remuneration Policy on pages will be subject to a binding Shareholder vote at the 2025 AGM, and if approved, would be expected to be effective from 15 May 2025 and remain in force until the AGM in 2028 with no requirement to vote again on the Policy in the intervening years provided that no substantive changes are proposed. Conclusion The Committee believes the proposals put forth in this report will properly motivate our Non-Employee Directors and our CEO to deliver sustainable growth and shareholder value over the long term and do so in a responsible and cost-efficient manner. I hope that you find the information in this report helpful, and look forward to the AGM, where we hope to have your support.

| Yours sincerely              |
| Ms. Kristine Peterson        |
| Remuneration Committee Chair |
| 24 March 2025                |

A-4

TABLE OF CONTENTS

Directors’ Remuneration Policy Period Covered by the Directors’ Remuneration Report Immunocore Holdings Limited was incorporated under the laws of England and Wales on 7 January 2021. Following a subsequent corporate reorganisation, Immunocore Holdings Limited became the ultimate parent company of the Group and was re-registered as